MedTrace Logo

Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients

NCT02565082 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2016-07-26

No results posted yet for this study

Summary

Sickle cell disease is a genetic disorder caused by a point mutation on the amino acid sequence of the β chain of hemoglobin.

The most expressive and most frequent complication of the disease is vaso-occlusive crisis, dominated by a painful syndrome. In addition to vaso-occlusive crises, many more chronic biological disturbances are observed in sickle cell patients.Sickle cell disease is considered nowadays as a hypercoagulable state.

However, the approach used so far to the measure of clotting in sickle cell disease was segmented in the sense that the various components of the hemostatic balance were studied separately.The thrombin generation test is a functional test which explores the coagulation globally, integrating both pro players that anticoagulants actors in the system. The investigators already used this test to demonstrate that the hemostatic potential was high in a cohort of affected children compared to control children of the same age.

This test will be used to characterize the hemostatic potential of adult sickle cell patients followed at the CHU Brugmann Hospital.

Conditions

Interventions

OTHER

Blood sampling - healthy volunteers

Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.

OTHER

Blood sampling - sickle cell patients arm - stable condition

Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.

OTHER

Blood sampling - sickle cell patients arm- exsanguinotransfusion needed

Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.

OTHER

Blood sampling - sickle cell patients arm - vaso-occlusive crisis.

Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.

Sponsors & Collaborators

  • Brugmann University Hospital

    lead OTHER

Principal Investigators

  • Anne Demulder, MD · CHU Brugmann

  • Bhavna Mahadeb · St Pierre Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02565082 on ClinicalTrials.gov